Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer
Details : Cisplatin is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Oropharyngeal Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 05, 2023
Lead Product(s) : 67-Cu MeCOSar-Tyr3-octreotate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Clarity Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Clarity and Cardinal Health Enter into Agreement for Targeted Copper Theranostics
Details : Cardinal Health will provide cGMP product manufacturing of ready-to-use TCT for Clarity’s U.S.-based clinical trials from its Center for Theranostics Advancement. TCT are radiopharmaceuticals that pair copper-64 (64Cu) and copper-67 (67Cu) for diagnosi...
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
December 02, 2021
Lead Product(s) : 67-Cu MeCOSar-Tyr3-octreotate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Clarity Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Vicineum
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Carisma Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Cardinal Health will provide comprehensive end-to-end 3PL to Sesen Bio in support of commercialization in the U.S. The Company’s lead program, Vicineum is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, ...
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
October 19, 2020
Lead Product(s) : Vicineum
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Carisma Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Paracetamol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Chinese University of Hong Kong
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Bioequivalence Study on Two Paracetamol Tablet Formulations
Details : Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 19, 2018
Lead Product(s) : Paracetamol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Chinese University of Hong Kong
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 99m-Tc Tilmanocept is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anus Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
August 05, 2016
Lead Product(s) : Loxoprofen Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Recipient : Lead Chemical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Loxoprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Muscle Fatigue.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 11, 2015
Lead Product(s) : Loxoprofen Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Recipient : Lead Chemical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium
Details : 99m-Tc Tilmanocept is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Endometrial Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
October 28, 2015
Details : 99m-Tc Tilmanocept is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Uterine Cervical Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
July 28, 2015
Details : 99m-Tc Tilmanocept is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhabdomyosarcoma.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
July 28, 2015
Reset All
